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Abstract
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common
inherited kidney disease, leading to kidney failure in most patients. In approximately
85% of cases, the disease is caused by mutations in PKD1. How dysregulation of
PKD1 leads to cyst formation on a molecular level is unknown. Induced pluripotent
stem cells (iPSCs) are a powerful tool for in vitro modeling of genetic disorders.
Here, we established ADPKD patient-specific iPSCs to study the function of PKD1
in kidney development and cyst formation in vitro. Somatic mutations are proposed
to be the initiating event of cyst formation, and therefore, iPSCs were derived from
cystic renal epithelial cells rather than fibroblasts. Mutation analysis of the ADPKD
iPSCs revealed germline mutations in PKD1 but no additional somatic mutations in
PKD1/PKD2. Although several somatic mutations in other genes implicated in
ADPKD were identified in cystic renal epithelial cells, only few of these mutations
were present in iPSCs, indicating a heterogeneous mutational landscape, and possi-
bly in vitro cell selection before and during the reprogramming process. Whole-
genome DNA methylation analysis indicated that iPSCs derived from renal epithe-
lial cells maintain a kidney-specific DNA methylation memory. In addition, compari-
son of PKD1+/− and control iPSCs revealed differences in DNA methylation
associated with the disease history. In conclusion, we generated and characterized
iPSCs derived from cystic and healthy control renal epithelial cells, which can be
used for in vitro modeling of kidney development in general and cystogenesis in
particular.
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1 | INTRODUCTION
Polycystic kidney disease (PKD) is a heterogeneous group of diseases
that can be inherited or acquired. Autosomal dominant polycystic kid-
ney disease (ADPKD) is the most common heritable form of PKD.
Over time, these patients gradually acquire numerous cysts in both
kidneys, resulting in renal function decline. Symptomatic treatment
consists of blood pressure control, pain, and infection management. In
addition, a vasopressin receptor antagonist (Tolvaptan) has become
available, slowing renal decline in ADPKD patients with rapid pro-
gressing disease.1-3 However, most patients develop kidney failure
and need a dialysis of a kidney transplantation before the age of 60.4
ADPKD is caused by a heterozygous germline mutation in PKD1
(~85%), PKD2 (~15%), or GANAB (~0.3%).5-7 PKD1 encodes for
polycystin-1, a transmembrane protein, which structurally looks like a
receptor or adhesion molecule and forms a complex with polycystin-
2, a calcium channel encoded by PKD2. GANAB, the alpha subunit of
glucosidase II (GIIα), plays a role in glycosylation and quality control of
polycystin-1 in the endoplasmic reticulum.7 Expression of polycystin-
1 is high in the fetal kidney and essential for kidney development.8,9
After nephron formation has completed, PKD1 expression is reduced.
In the adult kidney, the exact function of PKD1 is unclear, but it is
required in the renal epithelium to prevent cyst formation.
Cysts arise focally. The so-called “second hit model” refers to the
observation that all renal epithelial cells harbor a heterozygous muta-
tion, but only a small proportion of the cells will form a cyst. In this
model, somatic mutations affecting the remaining healthy PKD1 allele
are proposed to precede cyst initiation. This hypothesis is supported
by the observation that heterozygous Pkd1 mice develop only a few
cyst, whereas (kidney specific) inducible knock out of both Pkd1 alleles
results in a severe cystic phenotype including renal failure, thus reca-
pitulating the human phenotype.10 Further evidence supporting this
second hit model came from mutational studies on DNA from cyst lin-
ing epithelium, isolated from human kidney tissue samples, which dis-
played small somatic mutations or loss of heterozygosity (LOH) in
PKD1 or PKD2.11-15 Moreover, the second hit might also be present in
genes other than the one affected in the germline. Evidence for this
trans-heterozygous hypothesis is the identification of somatic muta-
tions in PKD2 in cyst DNA from patients with a PKD1 germline
mutation and vice versa.15,16 Also copy number variations (CNVs) and
small pathogenic somatic mutations at various loci in the genome of
cyst lining cells have been reported.17,18 However, the contribution of
these mutations to cyst initiation has not been proven.
Conversely, there is also evidence against the second hit model.
The second hit model does not explain cyst formation in autosomal
recessive PKD, in which patients harbor a trans-heterozygous muta-
tion in PKHD1. Nor can it explain the rare patients who are trans-
heterozygous for an incompletely penetrant PKD1 allele and a patho-
genic PKD1 allele.19 In these cases, patients already have both alleles
mutated and still exhibit focal cyst formation. Moreover, Pkd1+/−
mice develop cysts shortly after induction of renal injury, indicating
Pkd1 is haploinsufficient and a second hit in Pkd1 is not required for
cystogenesis.20 Finally, cystogenesis can also be provoked in normal
kidneys—without a germline mutation in a PKD gene—by applying
renal injury through drugs or ischemia.21-24
Therefore, another mechanism for cyst formation has been pro-
posed; the gene dosage model.25 This model hypothesizes that a vari-
ation in PKD1 dosage is the underlying cause of cystogenesis.
Reduction of PKD1 expression levels could be the result of stochastic
Significance statement
Autosomal dominant polycystic kidney disease (ADPKD) is
the most common inherited kidney disease, leading to kid-
ney failure in most patients. In approximately 85% of cases,
the disease is caused by mutations in PKD1. How dys-
regulation of PKD1 leads to cyst formation on a molecular
level is unknown. The present study has generated induced
pluripotent stem cells (iPSCs) of ADPKD patients to study
the function of PKD1 in kidney development and cyst for-
mation in vitro. The iPSCs revealed germline and autosomal
mutations implicated in ADPKD and displayed an epigenetic
memory of kidney epithelial cells, providing powerful models
to study ADPKD in vitro.
CYST EPITHELIAL DERIVED IPSCS FROM ADPKD PATIENTS 479
transcription fluctuations or inactivation of the PKD1 gene by DNA
methylation. Indeed, it was shown in mice that lowering Pkd1 expres-
sion to approximately 10% of the original level results in a cystic phe-
notype.19,26 Interestingly, also an increase in Pkd1 expression was
found to result in a cystic phenotype, confirming that regulation of
proper PKD1 levels is crucial.27,28
In the last decade, induced pluripotent stem cells (iPSCs) have
proven to be a powerful in vitro system for studying human genetic
disorders.29,30 The advantage of these iPSCs is their self-renewing
capacity, allowing indefinite expansion. This enables the use of a well-
characterized cell line for longer periods of time, reducing variation
between experiments and allowing genome editing. Moreover, iPSCs
are monoclonal. Importantly, recently developed protocols to differen-
tiate iPSCs into kidney organoids make it a suitable system to study
kidney development.31-33
Previously, iPSCs cells have been established from ADPKD
patients heterozygous for a PKD1 mutation.34-37 Since these iPSCs
were derived from fibroblasts, somatic mutations that might have
contributed to cystogenesis will be missed. Second, several studies
have shown that iPSCs retain an epigenetic signature of the tissue of
origin.38-40 This residual epigenetic memory could contribute to a
more efficient, directed differentiation back to the tissue of ori-
gin.41,42 In this study, we established iPSCs derived from ADPKD
patient cystic epithelial cells and from normal control kidney epithe-
lial cells. Whole-genome mutational analysis revealed heterozygous
germline mutations in PKD1 in all patients but no second hit in PKD1
or PKD2. Genome-wide DNA methylation analyses showed little dif-
ferences between PKD1+/− and normal kidney-derived iPSCs, but
did reveal a kidney-specific DNA methylation memory in renal epi-
thelial derived iPSCs, not present in ESCs. These ADPKD iPSCs may
provide a powerful model to study PKD1 function and the involve-
ment of the second hit in cyst formation and kidney development
in vitro.
2 | RESULTS
2.1 | Generation and characterization of normal
and cystic epithelial primary cells
To generate human iPSC models, we established primary renal tubular
epithelial cell (TEC) cultures from ADPKD kidney explants (Figure 1A).
Each cell line was derived from a unique cyst, by using the inner epithe-
lial monolayer of individual cysts. As controls, normal TECs were iso-
lated from unaffected regions of kidneys that were resected because of
a malignancy. In total, eight TEC lines were derived from two ADPKD
patients and two normal individuals (Table 1). Both cyst-derived as well
as healthy control TECs displayed a typical epithelial morphology and
no difference in karyotype stability (Figure 1B, Figure S1). To further
confirm the epithelial origin of the TECs, we applied immunocytochem-
istry staining for epithelial junctionmarkers (β-catenin and ZO-1), which
showed an epithelial-like honeycomb pattern, similar to an immortal-
ized renal epithelial cell line (RPTEC/hTERT; Figure 1B). In addition,
TECs were positive for KRT7, a renal epithelial marker, and negative
for fibronectin, a mesenchymal marker, which is highly expressed in
primary human fibroblasts (Figure 1B). These findings were supported
by quantitative real-time PCR (qRT-PCR), revealing expression of
epithelial junction markers (OCLN, Occludin and CDH1, E-cadherin) and
renal epithelial markers (SLC2A1 and L1CAM) in all TEC cell lines
(Figure 1C). In contrast, these cell lines did not express SNAI2/Slug, a
mesenchymal marker (Figure 1C). These results confirm that the TEC
lines are of epithelial origin.
2.2 | Cyst-derived TECs harbor somatic mutations
in various genes but not in PKD1
Both patients were diagnosed with ADPKD based on established clini-
cal criteria.43 To investigate whether the patients carried a germline
mutation in PKD1 and to test if additional somatic mutations were
present in PKD1 or in other genes, we performed whole exome
sequencing (WES) on TEC lines derived from three unique cysts, for
each patient. We found a heterozygous, pathogenic (truncating/frame
shift) mutation in PKD1, in exon 41 and 15 in patients 6 and 9, respec-
tively (Figure 2A). We did not detect additional somatic mutations in
PKD1 in individual cyst-derived TEC lines. However, because we
could not exclude that small mutations (eg, single nucleotide varia-
tions and insertions/deletions or LOH in PKD1 were missed in the
WES data), we performed Long Range PCR (LR-PCR) sequencing and
multiplex ligation-dependent probe amplification (MLPA) for PKD1
specifically and found no somatic mutations in PKD1 (data not shown).
To test whether de novo DNA methylation was present at the
remaining wild-type allele of PKD1, which could lead to gene silencing,
we applied MeD-seq. This technique utilizes the methylation-
dependent restriction enzyme LpnPI to detect DNA methylation
changes. MeD-seq analysis did not reveal increased promoter methyl-
ation of the unaffected PKD1 allele or changes in DNA methylation in
the transcription start site (TSS, ± 1 kb), the gene body (starting 1 kb
downstream of TSS until the transcription end sequence), as well as in
gene proximal or distal regions (Figure 2B and data not shown), nor
did we find increased DNA methylation of the PKD2 or PKHD1 alleles
suggesting that these genes have not been affected by epigenetic
silencing mechanisms (Figure S2A,B). To test whether the PKD1 or
PKD2 mRNA expression level was affected in the ADPKD patient-
derived TECs, we performed qRT-PCR, showing variation in expres-
sion level between samples, but no differences between ADPKD and
normal TECs (Figure 2C). The lack of a second mutation in either
PKD1 or PKD2 prompted us to test for the presence of other somatic
mutations that might explain cyst formation. Somatic mutations were
called through inter cyst comparisons (within each patient) only con-
sidering exonic regions and excluding synonymous mutations, identi-
fying a total of 3 to 15 somatic mutations per cyst (Figure 2D). All
mutations were heterozygous, or present in a fraction of the TEC
cells, and except for MUC2 were unique for one cyst. One cysts con-
tained a pathogenic somatic mutation in IFT140, a ciliopathy gene that
causes a cystic kidney phenotype,44 suggesting that this second hit
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could have had played a role in cyst initiation. For the other muta-
tions, no established relationship with PKD has been reported yet.
Thus, our analysis identified germline mutations in PKD1 but no
somatic mutations in PKD1 or PKD2. Nonetheless, somatic muta-
tions unique for individual cysts were found in various genes which
may have contributed to cyst initiation in a trans-heterozygous
manner.
2.3 | Cystic and normal renal epithelial cells can be
reprogrammed to iPSCs
Next, we established iPSCs of the TEC lines obtained from patients
6, 9, and controls. Of each primary TEC culture, one subclone was
used to establish either patient-derived-cyst-iPSC or control renal-
epithelium-iPSCs. Early passage TECs were transduced with a
F IGURE 1 Generation and validation of normal and PKD-patient derived tubular epithelial cells (TECs). A, Experimental setup: autosomal
dominant polycystic kidney disease explants were used to isolate primary TECs, which were reprogrammed into induced pluripotent stem cells
(iPSCs). B, Phase contrast microscopy and immunocytochemistry staining of junction markers ZO-1 (tight junction) and β-catenin (adherens
junction), renal epithelial marker Keratin-7, and mesenchymal marker fibronectin (scale bar = 50 μm for all panels). C, qRT-PCR to determine
expression of epithelial markers OCLN/Occludin (tight junction) and CDH1/E-cadherin (adherens junction), renal tubular markers SLC2A1 and
L1CAM, and a mesenchymal marker SNAI2/Slug. RPTEC/hTERT cells and primary human fibroblasts were used as a positive and negative control,
respectively. Ct values were normalized for GAPDH. The experiments were performed in triplicate twice; error bars represent the SD of both
experiments
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polycistronic lentiviral vector expressing OCT4, SOX2, KLF4, and
MYC, and a tdTomato reporter, under the control of a retroviral pro-
moter (SFFV) that is rapidly silenced during the reprogramming pro-
cess.45 Although an equal number of (TEC) cells was plated for
transduction, cystic TECs were growing notably slower, resulting in a
lower confluence at the time of transduction reducing iPSC colony
formation efficiency. However, we did establish over 10 iPSC colonies
for each of the original TEC lines. TdTomato-negative iPSC colonies
emerged from day 19 post-transduction onward. Morphologically, no
differences between PKD and normal iPSC colonies were observed.
Two iPSC colonies from each TEC parental line were chosen for fur-
ther characterization. These clones were grossly karyotypically normal
(Figure S3A,B) and displayed expression of the nuclear stem cell
markers, OCT4 and NANOG, and the stem cell surface marker
TRA-1-81, determined by immunocytochemistry (Figure 3A and
Figure S4). This was confirmed by qRT-PCR indicating expression of
the stem cells genes NANOG, OCT4, SOX2, and REX1, at levels compa-
rable to the human embryonic stem cell (hESC), but not expressed in
the parental TEC lines (Figure 3C). Embryoid body (EB) differentiation
of iPSCs followed by immunocytochemistry staining detecting
F IGURE 2 Germline and somatic mutation analysis cyst derived tubular epithelial cells (TECs). A, Heterozygous germline mutations in patient
6 and patient 9 present in TECs from 3 cysts result in a frameshift. B, MeD-seq analysis of PKD1 showing read-count scores per LpnPI site,
revealing no increased DNA methylation in TECs obtained from cyst lining epithelium (promoter shown in blue). C, mRNA expression levels of
PKD1 and PKD2 in TECs and iPSCs (qRT-PCR), normalized by the average of two housekeeping genes; actin and GAPDH, error bars represent the
SD. D, Somatic mutations observed by whole-exome sequencing comparing cysts of the same patient
TABLE 1 Patient characteristics
Patient number Phenotype Gender Age Germline mutation Clinical features TEC lines iPSC lines
6 PKD Male 58 PKD1 c.11450delG/
p.Gly3817fs (exon 41)
Infection 6.1/6.2/6.3 6.1A/6.1B
9 PKD Male 45 PKD1 c.4969delA/
p.Arg1657fs (exon 15)
Space transplant 9.1/9.2/9.3 9.1A/9.1B
29 Healthy control Male 41 NA Tumor 29.1 29.1A/29.1B
30 Healthy control Male 58 NA Tumor 30.1 30.1A/30.1B
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ectodermal (TUJ), mesodermal (Vimentin), and endodermal (AFP)
marker gene expression indicated that the renal-derived iPSCs pos-
sessed the capacity to differentiate in all three embryonic germ layers.
This was confirmed at the RNA level by qRT-PCR (Figure 3B,D and
Figure S5). Our findings demonstrate that our renal epithelial derived
iPSCs are genuine pluripotent stem cells.
2.4 | Mutational and DNA methylation analysis
of iPS cell lines
Each of the generated iPS cell lines represents an expanded single epi-
thelial cell of the cyst. To investigate the mutational landscape in more
detail, we performed WES on two iPS cell lines generated of TEC
F IGURE 3 Establishment and
characterization of polycystic kidney disease
(PKD) patient and normal renal epithelial
derived induced pluripotent stem cells
(iPSCs). A, Bright field picture of morphology
of representative PKD and wild-type iPSC
colonies. Shown are immunocytochemistry
stainings for stem cell markers: OCT4,
TRA-1-81, NANOG (scale bar = 100 μm for
all panels). B, Random differentiation if iPSCs
to embryoid bodies. Immunocytochemistry
stainings for markers of all three germ layers:
ectoderm (TUJ), mesoderm (Vimentin),
endoderm (AFP) (scale bar = 50 μm for all
panels). C, qRT-PCR, detecting expression of
endogenous pluripotency genes; NANOG,
OCT4, SOX2, and REX1, iPSC lines and the
parental tubular epithelial cell lines and
positive control human embryonic stem cells
(hESCs). D, Random differentiation of iPSCs
to embryoid bodies. Expression of genes
specific for each of the three germ layers is
shown by qRT-PCR; hESCs were used as
negative control
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clones 6.1 and 9.1. To exclude de novo mutations potentially intro-
duced during derivation of the iPS cell lines, we focused on mutations
observed in the inter TEC comparisons described in Figure 2D. This
analysis indicated that only two of the mutations observed in our TEC
lines were present in all the iPSCs, indicating heterogeneity in the
mutation spectrum in the TEC lines (Figure 4A).
Previous studies have indicated the presence of epigenetic mem-
ory of donor cells in the generated iPSCs. To test whether renal
F IGURE 4 Inheritance of genetic and epigenetic polycystic kidney disease (PKD)-associated modifications. A, Variant allele frequency of
somatic mutations observed in tubular epithelial cell (TEC) lines 6.1 and 9.1, also observed in induced pluripotent stem (iPS) cell lines 6A/B and
9A/B, respectively, are shown. B, Total number of uniquely called differentially methylated regions (DMRs, TSS, CpG island, and gene body)
excluding overlapping regions. C, MeD-seq profiles for the ZNF667 locus in wild-type TEC, renal epithelium-derived iPSC and embryonic stem cell
lines. D, Unsupervised hierarchical clustering analysis of PKD and control iPSCs based on transcription start site DMRs observed between inter
cell line comparisons. E, Overview of the number of DMRs observed in genome-wide comparisons between PKD and control iPSC lines.
F, MeD-seq profiles showing a DMR observed between PKD and control iPSCs in an lncRNA gene. G, Gene Ontology (GO) analysis of genes
hypermethylated DMRs in gene body region in PKD iPSCs
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epithelial derived iPSCs retain renal epigenetic memory during iPS
reprogramming, which might be beneficial for iPSC differentiation
toward the renal lineage, we applied MeD-seq on DNA isolated from
undifferentiated iPSC clones, hESCs, and TEC lines. Differentially
methylated regions (DMRs) between three predetermined groups, six
iPSC lines (PKD patient and controls), five control ESCs, and four renal
epithelial cell lines were detected genome-wide using a sliding win-
dow approach. Statistically significant regions with a more than two-
fold difference in read count were selected. This analysis revealed
that our iPSCs were properly reprogrammed showing demethylation
of the HoxA locus and loci involved in pluripotency (Figure S6A and
data not shown). Hierarchical clustering based on genome-wide DMRs
detected between TEC-iPS-hES indicated that iPS cell lines derived
from kidney epithelium cluster away from hES cell lines except huES8,
suggesting the presence of a kidney epithelial epigenetic signature
(Figure S6B). Indeed, inter TEC-iPS-ES comparisons indicated many
more TSS, CpG island. and gene body-associated DMRs that were
unique to ES than to iPS cells indicative for the presence of an epige-
netic heritage of TECs (Figure 4B,C and Figure S6C).
Next, we compared cyst-derived and control renal-epithelial iPS
cells to test whether we could detect differences in DNA methylation
associated with disease history. Hierarchical cluster analysis based on
regions that were differentially methylated between PKD and control
samples clustered PKD iPS cells away from WT iPS cells (Figure 4D).
Genome-wide determination of DMRs using a sliding window
approach revealed 207 DMRs between PKD and control iPSCs
(Figure 4E,F). Gene ontology (GO) analysis with PKD-specific signifi-
cantly hypermethylated gene body DMRs did retrieve GO terms like
cell-cell adhesion and cell-cell signaling, processes which are impli-
cated to be disturbed in PKD (Figure 4G). These results indicate that
renal iPSCs are reprogrammed into pluripotent iPSCs but display an
epigenetic signature of the TECs they have been derived of, providing
powerful models to study PKD disease by in vitro differentiation.
3 | DISCUSSION
Here, we have generated iPSCs from cystic renal epithelial cells. iPSCs
from healthy renal epithelial cells have been established
previously,46,47 but this was not yet done from cyst cells. We found
that our cyst-iPSCs contain somatic mutations, but only a few of these
mutations were also present in TECs they were derived from. In addi-
tion, we show that these renal-iPSCs retain residual epigenetic kidney
memory, which can be beneficial in directed differentiation to kidney
organoids.
Using WES and additional mutation analysis of PKD1 specifically
(LR-PCR and MLPA), we found that both ADPKD patients have
germline mutations in PKD1, but we did not find somatic mutations in
or LOH of PKD1 in TECs derived from cysts of these patients. In addi-
tion, we did not detect reduced PKD1 mRNA levels. Off note, we also
did not detect increased methylation in the promotors of PKD1,
PKD2, or PKHD1, suggesting that epigenetic silencing of these genes
did not lead to cystogenesis. The fact that we did not find genetic
mutations nor epigenetic alterations in PKD1 could mean that a sec-
ond hit did not occur in PKD1 or PKD2, but that merely the germline
mutation leads to haploinsufficiency which is in line with previous
findings that Pkd1+/− mice develop a cystic phenotype when renal
injury is induced.20 Alternatively, a second hit in PKD1 may have
occurred in the cyst but was lost during culture of the primary TECs
used in this study. This could be explained by polyclonality of the
cysts, as reported previously,48 or a growth advantage in cell culture
of cells with a single germline mutation over cells that were PKD1 null,
as were reported for other systems, were cancer cells, or were out-
grown by wild-type cells in standard culture conditions.49
Remarkably, we found several somatic mutations in genes other
than PKD1 or PKD2, ranging from 3 to 15 mutations per cyst. This is
in line with a recent study showing that cyst cells contain somatic
mutations in non-PKD1/PKD2, ciliopathy, or cancer-related genes.18
In concordance with that, many of the genes affected by a somatic
mutation identified in our analysis are also linked to the cilium or can-
cer. Moreover, in one TEC line, a somatic mutation was found in
IFT140, a gene that causes a cystic kidney phenotype in mice.44 In
addition, some of the affected genes are known to function in path-
ways previously linked to cystogenesis; ITCH, as a negative regulator
of Wnt signaling like PKD1 itself,50 and ENG, being a component of
the transforming growth factor beta receptor complex, also a pathway
implicated in PKD.51,52 Finally, MUC2 is a family member of the mucin
MUC1, a gene causing autosomal dominant tubulointerstitial kidney
disease.53 Somatic mutations in non-PKD1/PKD2 genes found by us
and others could be merely bystander mutations due to local damage.
This may explain the relative low variant allele frequency that we
observed as a representation of a heterogeneous population cells with
different mutations and is in line with our findings that only a few
mutations are found back in reprogrammed iPS cell lines. Alterna-
tively, these mutations might have played a role in cyst initiation, but
an ex vivo growth advantage of unaffected cells might have dimin-
ished the variant allele frequency.
Several previous reports have shown that residual DNA-
methylation provides a transcriptional memory and favors directed
differentiation back to the lineage of origin.40-42 When comparing the
DNA methylation profiles of human ESCs, renal derived iPSCs, and
the parental renal TEC lines, we found many more ESC than iPS
unique DMRs, indicating the presence of an epigenetic memory in
reprogrammed iPSCs. Whether this memory is related to the repro-
gramming process itself or to the cell type of origin needs further
investigation including MeD-seq analysis on reprogrammed fibro-
blasts. Nevertheless, iPSCs generated from PKD cyst epithelial cells
did contain many DMRs when compared with iPS cells generated
from control material, suggesting that at least some of the epigenetic
heritage is kidney epithelial specific. GO analysis of genes displaying
gene body hypermethylation, identifying active genes or genes with
an active history, revealed these genes to function in cell–cell interac-
tion and cell orientation, suggesting an (renal) epithelial DNA methyla-
tion profile representative for the disease history. We therefore
conclude that iPS cell lines derived from kidney epithelial cell lines dis-
play a kidney epithelial as well as disease-specific epigenetic memory.
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R-iPSCs may therefore represent better models to differentiate to kid-
ney organoids in terms of differentiation efficiency and resemblance
of the in vitro organoids to the actual kidney.
4 | METHODS
4.1 | Sample collection and TEC culture
Polycystic kidney explants were obtained from patients diagnosed with
ADPKDbased on radiological imaging.43 Collection was approved by the
Medical Ethics Committee of the Erasmus Medical Center
(MEC20130-188). TEC culture isolation protocol was adapted from
Klinkel et al54 and performed as follows: samples were immediately
placed on ice. Membranous layers were aseptically removed from the
kidney, and cyst, which were filled with clear fluid, were carefully dis-
sected. The inner epithelial layer of cysts were separated manually from
the cyst wall, washed with phosphate-buffered saline (PBS), and cut into
small fragments of approximately 1 mm2. Normal control kidney samples
were also washed in PBS and cut into fragments of the same size. Next,
the kidney fragments were plated on 0.2% gelatin-coated 10-cm plates
and incubated until fragments had adhered to the plate after which the
TECmediumwas carefully added; TEC-medium: DMEM:Ham's F12 (1:1)
media (Gibco life), supplementedwith 100 U/mLpenicillin-streptomycin,
100× Insulin-Transferrin-Selenium (Thermo Fisher Scientific), 40 pM
triiodo-L-thyronine (Sigma), 36 ng/mL hydrocortisone (Sigma), 10 ng/mL
recombinant human EGF (Peprotech). Medium was refreshed two to
three times a week, and cells were passaged by trypsinization when
reaching 80% confluence.
4.2 | TEC reprogramming into iPSC with lentiviral
vector
TEC with a low passage number (p4-p5) were used for reprogramming.
For each TEC line, a total of 2 × 105 cells/well were plated in a six-well
culture plate coated with 0.2% gelatin. The following day, TECs were
transduced with a lentivirus encoding OCT, SOX2, KLF4, c-MYC.45 To
increase the efficiency of viral transduction, 4 μg/mL of polybrene
(Invitrogen) was added. Day 4 post-transduction, cells were replated on
gamma-irradiated mouse embryonic fibroblasts (MEFs). The next day,
the media was converted to hESC media (DMEM/F12, 20% knock-out
serum, 1% L-glutamine, 1% nonessential amino acids, 0.1 mM
β-mercaptoethanol, 10 ng/mL basic fibroblast growth factor [bFGF]).
Between days 2 and 9, 2 mmol/L of valproic acid was added daily.
Around day 26 onward, the iPSC colonies were picked and expanded.
4.3 | Karyotype analysis
iPSCs were cultured in feeder-free conditions on Geltrex coating (Gibco,
A1413301) and in E8 medium (Gibco, Cat A14666SA). Cells were har-
vest using TrypLE Express Enzyme (Gibco, LS12604021) and collected in
a 15-mL tube with E8 medium supplemented with (10 μg/mL) Colcemid
(Gibco 15 210-040) and incubated at 37C for 30 minutes. Next, cells
were treated with 0.075 M KCl for 10 minutes at 37C and another
10 minutes at room temperature (RT). Cells were fixedwith fresh Carny's
fixative solution (3:1 methanol:acetic acid), streaked onto glass slides and
stained with Vectashield Mounting with DAPI (Vector Laboratories,
H-1200). At least 10metaphases were analyzed per iPSC line. For karyo-
type analysis of TECs, cells were cultured in TEC medium and treated
with (12 μg/mL) Colcemid (Gibco 15 210-040) at 37C for 6 hours. Next,
cells were harvest using TrypLE Express Enzyme and processed with the
HANABI chromosome harvester (ADS Biotec) and stained with Quina-
crine. To map the deletions in our iPSC lines, SNP array analysis was per-
formed using Human CYTO SNP 12 version 1 arrays (Illumina, San
Diego, California), aligned to human genome build 19.
4.4 | In vitro differentiation of iPSCs to EBs
To induce EB formation, iPSCs were dissociated from the MEF feeder
layer using collagenase IV 1 mg/mL, harvested by centrifugation at
200g for 2 minutes and cultured on ultralow attachment six-well
plates (Corning) in hESC medium without bFGF. Medium was
refreshed every other day. Day 8 EBs were collected for RNA analysis.
For immunocytochemistry analysis, Day 8 EBs were seeded on Nunc
Lab-Tek chamber slide to attach and grow till day 16.55
4.5 | Immunocytochemistry iPSC/
TEC + microscopy
iPS cells were fixed for 15 minutes with 4% paraformaldehyde at RT
followed by permeabilization of the cells using 0.1% Triton X-100 (PBS)
for 10 minutes. After blocking (1% BSA, 0.05% Tween 20 in PBS) for
30 minutes, cells were stained for 1 hour at RT or overnight at 4Cwith
primary antibodies, followed by incubation with secondary antibodies.
Antibodies are listed in the Appendix (Table 1). Images were acquired
with a Leica SP5 confocal microscope and processed using Fiji.
4.6 | DNA isolation
Cells were collected by centrifugation after collagenase treatment and
lysed overnight at 37C in lysis buffer (0.2% sodium dodecyl sulfate
and 1 mg/mL Proteinase K). The next day, phenol and chloroform
extractions were performed and DNA was precipitated using iso-
propanol and washed with 70% ethanol. Finally, DNA was dissolved
in 10 mM Tris buffer (pH 7.5).
4.7 | Whole exome sequencing and analysis
Genomic DNA (gDNA) was collected from TECs at passage <5, DNAwas
sheared in a Covaris S220 instrument, and prepared for sequencing using
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SureSelectXT reagents and Clinical Research Exome capture baits
(Agilent Technologies). For the low-input samples (where less than 1 μg
genomic DNA was available), we used 200 ng input gDNA and the man-
ual sampleprep protocol provided by the manufacturer. For the
remaining samples, we used the automated sampleprep protocol on an
Agilent Bravo B system and up to 3 μg input gDNA. Sequencing was
done either on an Illumina HiSe2500 or HiSeq4000 system, for paired-
end 100 or 150, respectively. At least 5.2 Gbp of sequencing data per
samplewas generated. Sequence readsweremapped against human ref-
erence genome GRCh38 using Burrows-Wheeler Aligner (v0.7.12) with
default settings and supplying respective read-groups.56 In the case of
iPSC samples, sequence reads weremapped against both the human ref-
erence genome GRCh38 and mouse reference genome GRCm38 using
Burrows-Wheeler Aligner (v0.7.16a) with default settings. Afterwards,
reads originating from mouse were discarded by Disambiguate
(v1.0.0).57 After alignment and quality control, sequence reads originat-
ing from multiple lanes were merged using GATK PrintReads (v3.6.0)
prior to further analysis.58 Sequence duplicates were marked using
PicardTools (v1.129).59 Somatic and germline variant calling was per-
formed by Strelka2 (v2.8.3) using a matched-normal design with default
exome settings.60 In the absence of matched normal material (patients
6 and 9), randomized alternative cyst samples of the same patient were
used as substitute “matched-normal” reference. Variantswere annotated
with GENCODE annotations using ANNOVAR.61,62 Heuristic filtering
removed variants, which did not pass all standard Strelka2 post-calling
filters, had fewer than six total reads or had an allelic frequency above
0.02% in the ExAC population.63 CONTROL-FREEC (v11.0) was used to
detect copy-number aberrations using the samematched normal scheme
as previously described with default exome settings on SureSelect v5
target regions.64 Genomic datawere visualizedwith the R statistical plat-
formusing the TrackViewer and RCircos BioConductor packages.65,66
4.8 | LR-PCR-sequencing and MLPA of PKD1
For the repeated region of PKD1 (exon 1-33), an LR-PCR was used
followed by a nested PCR while the unique part (exon 33-46) and the
complete coding region of PKD2 was directly amplified. PCR products
were Sanger-sequenced using standard procedures (primers
sequences and conditions available upon request). For the detection
of larger deletions and duplications, two commercially available MLPA
kits (P351-B2 and P352-C1; MRC-Holland, Amsterdam, The Nether-
lands) were used according to the manufacturer's instructions.
4.9 | RNA isolation, cDNA synthesis, and
quantitative real-time PCR
TECs were lysed at passage < p5 in Tri reagent (Sigma) for 5 minutes.
After chloroform extraction, RNA was precipitated using isopropanol
and washed with 75% ethanol. RNA was dissolved in 20 μL DepC-
treated H20 and stored at −80C. To remove DNA, RNA samples
were incubated with 1 U DNase (Thermo Fisher Scientific) for
30 minutes at 37C. DNAse was stopped by incubating with EDTA
(25 mM) at 65C for 10 minutes. Random hexamers (stock 50 μM,
final 5 μM, Thermo Fisher Scientific) and dNTPs (10 mM) were added
and incubated 65C for 5 minutes. After denaturation, samples were
placed on ice and RT mix was added containing 5× first strand buffer,
DTT (0.1 M), and RNase out (company). Samples were incubated at
25C for 2 minutes. Next 200 U Superscript II was added (Thermo
Fisher Scientific) and incubated for 10 minutes at 25C and
15 minutes at 70C. Samples were stored at −20C. Quantitative real-
time PCR was performed in a 10-μL final reaction volume using Plati-
num Taq DNA polymerase (Life Technologies) and Sybr Green (Sigma
Aldrich) in a CFX 384 Real Time system (BioRad). Expression levels
were normalized to Actin/GAPDH. Primer sequences are listed in
Appendix (Table 2).
4.10 | MeD-seq sample preparation
DNA from iPSC samples collected at passage 12 were used for MeD-
seq analysis. LpnPI and MspJI (New England Biolabs) digestions were
carried out according to the manufacturer's protocol. Reactions con-
tained 50 ng in a 10-μL volume and digestion took place overnight in
the absence of enzyme activators. Digests of genomic DNA with LpnPI
resulted in snippets of 32 bp around the fully methylated recognition
site that contains CpG. The DNA concentration was determined by the
Quant-iT High-Sensitivity assay (Life Technologies; Q33120) and
50 ng ds DNA was prepared using the ThruPlex DNA-seq 96D kit
(Rubicon Genomics cat#R400407). Twenty microliters of amplified end
product was purified on a Pippin HT system with 3% agarose gel cas-
settes (Sage Science). Stem-loop adapters were blunt-end ligated to
repaired input DNA and amplified (4 + 10 cycles) to include dual-
indexed barcodes using a high fidelity polymerase to yield an indexed
Illumina NGS library. Multiplexed samples were sequenced on Illumina
HiSeq2500 systems for single read of 50 base pairs according to the
manufacturer's instructions. Dual-indexed samples were demultiplexed
using the bcl2fastq software (Illumina).
4.11 | MeD-seq data processing
Data processing was carried out using specifically created scripts in
Python version 2.7.5. Raw fastq files were subjected to Illumina adap-
tor trimming, mouse genome-specific reads were removed, and reads
were filtered based on LpnPI restriction site occurrence between
13 and 17 bp from either 50 or 30 end of the read. Reads that passed
the filter were mapped to hg38 using bowtie2.1.0. Multiple and
unique mapped reads were used to assign read count scores to each
individual LpnPI site in the hg38 genome. SAM and BAM files were
generated using SAMtools for visualization. Gene and CpG island
annotations were downloaded from UCSC (HG38). Genome-wide
individual LpnPI site scores were used to generate read count scores
for the following annotated regions: TSS (1 kb before and 1 kb after),
CpG islands and gene body (1 kb after TSS till TES).
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4.12 | MeD-seq data analysis
Data analysis was carried out in Python version 2.7.5. DMR detec-
tion was performed between two data sets containing the regions of
interest (TSS, gene body or CpG islands) using the chi-squared test
on read counts. Significance was called by either Bonferroni or FDR
using the Benjamini-Hochberg procedure. DMRs were used for
unsupervised hierarchical clustering (complete/city-block); the Z-
score of the read counts was used for normalization and is also
shown in the heatmaps. In addition, a genome-wide sliding window
was used to detect sequentially differentially methylated LpnPI
sites. Statistical significance was called between LpnPI sites in pre-
determined groups using the chi-squared test. Neighboring signifi-
cantly called LpnPI sites were binned and reported, DMR threshold
was set at a minimum of 10 LpnPI sites, a minimum size of 100 bp,
and either a twofold or fivefold change in read counts. Overlap of
genome-wide detected DMRs was reported for TSS, CpG island, and
gene body regions. GO analysis was performed in Gorilla (FDR-
adjusted).
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